Skip to main content
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest
  • facebook
  • twitter
  • linkedin
  • youtube
Home
  • About
    • About the Navigator
    • Navigator FAQs
  • Guides
    • For Patients and Caregivers
    • For Physicians and Healthcare Providers
    • For Companies and Sponsors
  • Company Directory
    • View Company Directory
    • Submit Company Information
  • Resources
  • Expanded Access eRequest

Clarity Pharmaceuticals Ltd

By jpalfreyman on Tue, 09/03/2024 - 16:18
  • Read more about Clarity Pharmaceuticals Ltd

Life Molecular Imaging Ltd (LMI)

By jpalfreyman on Tue, 09/03/2024 - 14:29
  • Read more about Life Molecular Imaging Ltd (LMI)

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

  • Read more about The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

Expanded Access Study of UC-MSC in DMD Patients

  • Read more about Expanded Access Study of UC-MSC in DMD Patients

Seasonal R21 Mass Vaccination for Malaria Elimination

  • Read more about Seasonal R21 Mass Vaccination for Malaria Elimination

Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

  • Read more about Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

COVID-19 Self-testing IMPROVE

  • Read more about COVID-19 Self-testing IMPROVE

Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

  • Read more about Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients

Expanded Access Program for RP in Adults

  • Read more about Expanded Access Program for RP in Adults

A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

  • Read more about A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Current page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Subscribe for updates from the Reagan-Udall Foundation for the FDA

Subscribe
(202) 849 - 2075
1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036
navigator@reaganudall.org
  • facebook
  • twitter
  • linkedin
  • youtube

© Reagan-Udall Foundation for the FDA
© Reagan-Udall Foundation for the FDA